Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Manifestations and Treatment in Korean Patients with X-Linked Agammaglobulinemia

성염색체 열성 범저감마글로불린혈증 환자의 임상 소견 및 치료

  • Cho, Hannah (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Kim, Joong Gon (Department of Pediatrics, Seoul National University Children's Hospital)
  • 조한나 (서울대학교 어린이병원 소아청소년과) ;
  • 김중곤 (서울대학교 어린이병원 소아청소년과)
  • Received : 2017.05.25
  • Accepted : 2017.07.24
  • Published : 2017.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in the Bruton's tyrosine kinase (Btk) gene. The aim of this study was to investigate the clinical manifestations, molecular features, and treatment status of XLA in Korean patients at Seoul National University Children's Hospital. Methods: Fourteen Korean boys with XLA showing serum agammaglobulinemia, non-detectable to less than 2% of peripheral B-cells, and mutation of the Btk gene were enrolled. We observed the clinical features, laboratory findings, status of treatment, and complications in these XLA patients. Results: All XLA patients had a history of recurrent bacterial infections before diagnosis, and 20% of them had a neutropenia. Of the XLA patients 35.7% had a family history of XLA and 75% of their mothers were carriers. Btk gene analysis showed variable gene mutations in Xq22 including 9 amino acid substitutions, 3 frameshifts, 1 premature stop codon, and 1 splice defect. After intravenous immunoglobulin replacement therapy, infection episodes decreased, but complications such as bronchiectasis and chronic sinusitis remained. Conclusions: In patients less than 4 years of age with recurrent infection, analysis of serum gamma globulin levels and the Btk gene are recommended for the early diagnosis of XLA and for the appropriate prevention of recurrent infection.

목적: 본 연구에서는 서울대학교 어린이병원에서 범저감마글로불린혈증(X-linked agammaglobulinemia [XLA])로 진단된 환자들의 임상적 증상 및 치료에 대해서 보고하고자 하였다. 방법: 14명의 남자 환자가 XLA로 진단되었으며 CD19+ B 세포가 2% 미만이며 Bruton's tyrosine kinase (Btk) 유전자 돌연변이가 있는 경우를 기준으로 하였다. 결과: 모든 XLA 환자에서 반복적인 세균성 감염이 있었고 환자의 20%에서 호중구 감소증이 있었으며 환자 어머니의 75%가 보인자였다. Btk gene study에서는 돌연변이가 다양한 부위에서 나타났으며 특정부위에서 집중적으로 발생하지는 않았다. 면역글로불린 정맥주사 후 반복적인 세균성 감염은 줄어들었으나 합병증으로 기관지 확장증이 14명 중 3명, 지속적인 부비동염은 4명에서 발생하였다. 결론: 4세 이전 세균 감염이 반복되는 경우 XLA와 같은 체액성 면역결핍을 의심하여 글로불린 검사를 하는 것이 조기 진단에 중요하며 Btk 유전자변이 검사를 시행하여 확진한 후 면역글로불린 정맥주사 및 예방적 항생제 등 적절한 치료를 통해 합병증을 줄이고 무 질병 상태를 유지할 수 있다.

Keywords

References

  1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8.
  2. Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 1996; 75:287-99. https://doi.org/10.1097/00005792-199611000-00001
  3. Khan WN, Sideras P, Rosen FS, Alt FW. The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Ann N Y Acad Sci 1995;764:27-38.
  4. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-33. https://doi.org/10.1038/361226a0
  5. Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002;141:566-71. https://doi.org/10.1067/mpd.2002.127711
  6. Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64:145-56. https://doi.org/10.1097/00005792-198505000-00001
  7. Farrar JE, Rohrer J, Conley ME. Neutropenia in X-linked agammaglobulinemia. Clin Immunol Immunopathol 1996;81:271-6. https://doi.org/10.1006/clin.1996.0188
  8. European Society for Immunodeficiencies. X-linked agammaglobulinemia [Internet]. Geneva: ESID; c2017 [cited 2017 Nov 16]. Available from: https://esid.org/Working-Parties/Clinical/Resources/Diagnostic- criteriafor-PID2#Q15.
  9. Nakagawa N, Imai K, Kanegane H, Sato H, Yamada M, Kondoh K, et al. Quantification of kappa-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 2011;128:223-5.e2. https://doi.org/10.1016/j.jaci.2011.01.052
  10. Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193-202. https://doi.org/10.1097/01.md.0000229482.27398.ad
  11. Rohrer J, Parolini O, Belmont JW, Conley ME, Parolini O. The genomic structure of human Btk, the defective gene in X-linked agammaglobulinemia. Immunogenetics 1994; 40:319-24. https://doi.org/10.1007/BF01246672
  12. Ohta Y, Haire RN, Litman RT, Fu SM, Nelson RP, Kratz J, et al. Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci U S A 1994;91:9062-6. https://doi.org/10.1073/pnas.91.19.9062
  13. Vihinen M, Brandau O, Branden LJ, Kwan SP, Lappalainen I, Lester T, et al. Btkbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res 1998;26: 242-7. https://doi.org/10.1093/nar/26.1.242
  14. Sweinberg SK, Wodell RA, Grodofsky MP, Greene JM, Conley ME. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol 1991;88:96-104. https://doi.org/10.1016/0091-6749(91)90306-9
  15. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999;134:589-96. https://doi.org/10.1016/S0022-3476(99)70246-5
  16. van der Meer JW, Weening RS, Schellekens PT, van Munster IP, Nagengast FM. Colorectal cancer in patients with Xlinked agammaglobulinaemia. Lancet 1993;341:1439-40. https://doi.org/10.1016/0140-6736(93)90883-I
  17. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210-2. https://doi.org/10.1016/j.jaci.2008.04.044
  18. Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am 2008;28:875-6. https://doi.org/10.1016/j.iac.2008.07.003
  19. Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, et al. Comparison of the efficacy of IGIVC, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003;3:1325-33. https://doi.org/10.1016/S1567-5769(03)00134-6
  20. Favre O, Leimgruber A, Nicole A, Spertini F. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 2005;60:385-90. https://doi.org/10.1111/j.1398-9995.2005.00756.x
  21. Bayrakci B, Ersoy F, Sanal O, Kilic S, Metin A, Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 2005;47:239-46.
  22. Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001;135: 165-74. https://doi.org/10.7326/0003-4819-135-3-200108070-00008
  23. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1: 1075-7.
  24. Pruzanski W, Sussman G, Dorian W, Van T, Ibanez D, Redelmeier D. Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 1996;20:353-9. https://doi.org/10.1007/BF01486738
  25. Sorensen RU, Polmar SH. Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med 1984;76(3A):83-90. https://doi.org/10.1016/0002-9343(84)90325-5
  26. Ochs HD, Fischer SH, Wedgwood RJ, Wara DW, Cowan MJ, Ammann AJ, et al. Comparison of high-dose and lowdose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984;76(3A):78-82.
  27. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354-60.e4. https://doi.org/10.1016/j.jaci.2010.02.040
  28. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010;137:21-30. https://doi.org/10.1016/j.clim.2010.06.012
  29. Rohrer J, Conley ME. Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood 1999;94: 3358-65.
  30. Howard V, Myers LA, Williams DA, Wheeler G, Turner EV, Cunningham JM, et al. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol 2003;107:98-102. https://doi.org/10.1016/S1521-6616(03)00045-7